Wall Street Breakfast: Must-Know News [View article]
"Drugmakers boosted prices for their 50 top-sellers by 7.82% in 2007, on the heels of 6.73% and 6.22% jumps in 2006 and 2005, in an effort to boost profits in the face of patent expirations and waning pipelines. The ploy could backfire by pushing government to beef-up its regulation of drug pricing."
Doesn't this mean that the decline in profits when these drugs hit patent expiration will be even sharper?
Wall Street Breakfast: Must-Know News [View article]
Doesn't this mean that the decline in profits when these drugs hit patent expiration will be even sharper?